Skip to main content

Advertisement

SpringerLink
Log in

Single Institute Experience with Neo-Adjuvant Chemotherapy and Interval Debulking Surgery in Advanced Endometrial Cancer

  • Original Article
  • Published:
Indian Journal of Surgical Oncology Aims and scope Submit manuscript

Abstract

Our study aims to review the role of neoadjuvant chemotherapy (NACT) followed by interval debulking surgery (IDS) in patients with advanced endometrial cancer. Patients with advanced endometrial cancer treated with NACT followed by IDS at our institute from January 2010 to January 2020 were recruited. Data pertaining to baseline patient characteristics, surgical details, histopathology/imaging reports, treatment and follow up details including the development of recurrence and death were collected from institutional database. Disease free survival (DFS) and overall survival (OS) were calculated using Kaplan Meier survival curves. We recruited 31 patients for our study. About 83.9% patients showed partial response and 6.4% patients responded completely to NACT with none of the patients developing disease progression. Complete cytoreduction was achieved in 90.3% patients, optimal cytoreduction in 3.2% patients while 6.5% patients had suboptimal surgery. On completion of primary treatment, complete remission was achieved by 80.6% patients while 16.1% patients had progressive disease. Median follow up period was 21 months (range 1- 61 months). During follow up period, 51.6% patients developed recurrent disease after achieving complete remission and 61.3% patients died of disease progression/recurrence. The median DFS and median OS of the cohort was 15 months and 21 months respectively. The 2 year DFS for the cohort was 34.1% and the 3 year OS was 30.5%. NACT followed by IDS is a reasonably good option for advanced stage endometrial cancer not amenable to primary surgery. Innovative treatments are warranted in this cluster of patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

Data Availability

Data will be made available on request.

References

  1. Mahantshetty U, Aggarwal A, Ganesh B et al (2013) Clinical outcome of early-stage endometroid adenocarcinoma: a tertiary cancer center experience. Int J Gynecol Cancer 23(8):1446–1452. https://doi.org/10.1097/IGC.0b013e3182a2ff46

    Article  PubMed  Google Scholar 

  2. Galaal K, Al Moundhri M, Bryant A et al (2014) Adjuvant chemotherapy for advanced endometrial cancer. Cochrane Database Syst Rev 2014(5):CD010681. https://doi.org/10.1002/14651858.CD010681.pub2

    Article  PubMed  PubMed Central  Google Scholar 

  3. Vergote I, Tropé CG, Amant F et al (2010) Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 363(10):943–953. https://doi.org/10.1056/NEJMoa0908806

    Article  CAS  PubMed  Google Scholar 

  4. Rabinovich A (2016) Neo-adjuvant chemotherapy for advanced stage endometrial carcinoma: a glimmer of hope in select patients. Arch Gynecol Obstet 293(1):47–53. https://doi.org/10.1007/s00404-015-3841-8

    Article  CAS  PubMed  Google Scholar 

  5. de Lange NM, Ezendam NPM, Kwon JS et al (2019) Neoadjuvant chemotherapy followed by surgery for advanced-stage endometrial cancer. Curr Oncol 26(2):e226–e232. https://doi.org/10.3747/co.26.4655

    Article  PubMed  PubMed Central  Google Scholar 

  6. Philp L, Kanbergs A, Laurent JS et al (2021) The use of neoadjuvant chemotherapy in advanced endometrial cancer. Gynecol Oncol Rep 36:100725. https://doi.org/10.1016/j.gore.2021.100725

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Wilkinson-Ryan I, Frolova AI, Liu J et al (2015) Neoadjuvant chemotherapy versus primary cytoreductive surgery for stage IV uterine serous carcinoma. Int J Gynecol Cancer 25(1):63–68. https://doi.org/10.1097/IGC.0000000000000321

    Article  PubMed  PubMed Central  Google Scholar 

  8. Bogani G, Ditto A, Leone Roberti Maggiore U et al (2019) Neoadjuvant chemotherapy followed by interval debulking surgery for unresectable stage IVB Serous endometrial cancer. Tumori 105(1):92–97. https://doi.org/10.1177/0300891618784785

    Article  PubMed  Google Scholar 

  9. Eto T, Saito T, Shimokawa M et al (2013) Status of treatment for the overall population of patients with stage IVb endometrial cancer, and evaluation of the role of preoperative chemotherapy: a retrospective multi-institutional study of 426 patients in Japan. Gynecol Oncol 131(3):574–580. https://doi.org/10.1016/j.ygyno.2013.08.036

    Article  PubMed  Google Scholar 

  10. Khouri OR, Frey MK, Musa F et al (2019) Neoadjuvant chemotherapy in patients with advanced endometrial cancer. Cancer Chemother Pharmacol 84(2):281–285. https://doi.org/10.1007/s00280-019-03838-x

    Article  PubMed  Google Scholar 

  11. Vandenput I, Van Calster B, Capoen A et al (2009) Neoadjuvant chemotherapy followed by interval debulking surgery in patients with serous endometrial cancer with transperitoneal spread (stage IV): a new preferred treatment? Br J Cancer 101(2):244–9. https://doi.org/10.1038/sj.bjc.6605157

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Gynae Oncology, Rajiv Gandhi Cancer Institute and Research Centre, Delhi, India

    Jahnvi Varshney, Subrata Debnath & Vandana Jain

  2. Department of Histopathology, Rajiv Gandhi Cancer Institute and Research Centre, Delhi, India

    Anila Sharma

  3. Department of Uro-Gynae Oncology, Rajiv Gandhi Cancer Institute and Research Centre, Delhi, India

    Sudhir Rawal

Authors
  1. Jahnvi Varshney
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Subrata Debnath
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Anila Sharma
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Sudhir Rawal
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Vandana Jain
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Authors confirm contribution to the paper as follows: Conceptualization- Dr. Vandana Jain; Data Curation- Dr. Jahnvi Varshney, Dr. Subrata Debnath; Formal Analysis- Dr. Jahnvi Varshney; Funding Acquisition- Nil; Methodology- Dr. Vandana Jain; Project administration- Dr. Jahnvi Varshney, Dr. Anila Sharma; Supervision- Dr. S.K. Rawal, Dr. Vandana Jain; Validation- Dr. Vandana Jain; Visualization- Dr. Vandana Jain; Writing original draft- Dr. Jahnvi Varshney; Writing- review and editing- Dr. S.K. Rawal, Dr. Vandana Jain.

Corresponding author

Correspondence to Vandana Jain.

Ethics declarations

The work has got institutional ethical committee clearance.

Requirement of written informed consent was waived off by IRB.

The manuscript has not been submitted to other journals simultaneously.

Disclaimer

This article has not been submitted to other journals simultaneously.

Disclosure

We have no financial disclosure.

Author Discloser Statement

No competing financial interests exist.

Conflicts of Interests

None

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Varshney, J., Debnath, S., Sharma, A. et al. Single Institute Experience with Neo-Adjuvant Chemotherapy and Interval Debulking Surgery in Advanced Endometrial Cancer. Indian J Surg Oncol 14, 800–808 (2023). https://doi.org/10.1007/s13193-023-01781-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13193-023-01781-1

Keywords

Search

Navigation